source
- Westlake-backed Vedana Therapeutics raises $46M to develop anti-PACAP migraine prevention drugsVedana Therapeutics, a new biotech formed out of stealth, announced it has secured $46 million in financing backed by Westlake. The capital will be used to advance its anti-PACAP antibody program a…
- FDA approves first generic single-dose baloxavir tablet for flu treatment and preventionFDA announced approval of the first generic version of Xofluza (baloxavir marboxil) tablets, a single-dose treatment for acute uncomplicated influenza and prophylaxis for patients five years of age…